Study 20180244 is a double-blind, randomized, placebo-controlled, multicenter outcomes study to assess the impact of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein (a). The primary objective is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death, myocardial infarction, or urgent coronary revascularization in these patients. Lipoprotein (a) reductions as anticipated with olpasiran are expected to result in clinically meaningful cardiovascular benefit in patients with ASCVD.